PRoFESS(R) Results Announced at XVII European Stroke ...(s of the study. Landmark trials like PR...),Health

The other regimen tested in PRoFESS investigated whether Micardis(R) tablets, combined with standard antiplatelet therapy, can further reduce the risk of recurrent stroke. At the end of the study, the results demonstrated that 8.7% of patients experienced recurrent stroke in the MICARDIS arm versus 9.2% in the placebo arm (p=0.23). Thus, the primary endpoint of superiority of MICARDIS versus placebo could not be statistically confirmed. The mean follow-up period was 2.5 years, and it is unclear whether a longer follow-up period would have yielded statistical significance. The PRoFESS results continue to support the safety and tolerability profile of MICARDIS.

"We are proud to have sponsored the PRoFESS study," said Dr. Thor Voigt, Senior Vice President, Medicine and Drug Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "We set out to advance the understanding of strategies for recurrent stroke prevention and will continue to evaluate the PRoFESS data to help physicians make more informed treatment decisions."

About PRoFESS(R)

PRoFESS(R) (Prevention Regimen For Effectively avoiding Second Strokes) was designed to examine the effects of different prevention regimens on recurrent stroke, including the antiplatelet agent AGGRENOX versus clopidogrel and the efficacy of MICARDIS, an antihypertensive, compared to placebo in preventing recurrent stroke in the presence of background standard antihypertensive therapy. The trial was a randomized, double-blind, placebo-controlled clinical study that included 20,332 patients from 695 sites in 35 countries, with a four-year follow-up of patients.

PRoFESS is a collaborative effort between academia and the sponsor, Boehringer Ingelheim. Co-funders of the telmisartan arm of the study in selected countries are Ba
'/>"/>